It's rare these days for an artist to ask for fewer microphones, but after warming up in our space, Billy Strings did just that. Surrounded by his band, the bluegrass virtuoso brings back the spirit ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...

In 1980, Stephen Hawking gave his first lecture as Lucasian Professor at the University of Cambridge. The lecture was called "Is the end in sight for theoretical physics?" Forty-five years later, ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Performances in N.Y.C. Georg Friedrich Haas has written a piece of almost ridiculous scale and complexity. The effect is awe-inspiring. Georg Friedrich Haas has written a piece of almost ridiculous ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...